Nephrocare Health Services Intrinsic Value
Nephrocare Health Services (NEPHROPLUS) median intrinsic value is ₹443.20 from 9 valuation models (range ₹210–₹1582), vs current price ₹699.10 — -36.6% downside (Trading Above Calculated Value), margin of safety -57.7%. For current market price and key ratios, visit Nephrocare Health Services share price screener.
NEPHROPLUS Valuation Methods Summary — DCF, Graham Number & P/E
Nephrocare Health Services intrinsic value across 9 models vs current price ₹699.10 — upside/downside and value range per method. Read NEPHROPLUS dividend growth for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹209.73 | ₹167.78 - ₹251.68 | -70.0% | EPS: ₹12.12, Sector P/E: 12x |
| Book Value Method | asset | ₹558.50 | ₹502.65 - ₹614.35 | -20.1% | Book Value/Share: ₹558.50, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹443.20 | ₹398.88 - ₹487.52 | -36.6% | Revenue/Share: ₹554.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹744.00 | ₹669.60 - ₹818.40 | +6.4% | EBITDA: ₹248.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1582.46 | ₹1265.97 - ₹1898.95 | +126.4% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹209.73 | ₹188.76 - ₹230.70 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹209.73 | ₹188.76 - ₹230.70 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹720.00 | ₹648.00 - ₹792.00 | +3.0% | ROE: 10.7%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹390.26 | ₹351.23 - ₹429.29 | -44.2% | EPS: ₹12.12, BVPS: ₹558.50 |
NEPHROPLUS Intrinsic Value vs Market Price — All Valuation Models
Nephrocare Health Services fair value range ₹210–₹1582 vs current market price ₹699.10 across 9 valuation models. Analyse NEPHROPLUS FII DII holdings to track promoter, FII and institutional holdings.
NEPHROPLUS Intrinsic Value Analysis — Undervalued or Overvalued?
Nephrocare Health Services median intrinsic value ₹443.20, current price ₹699.10 — Trading Above Calculated Value by 36.6%, margin of safety -57.7%.
What is the intrinsic value of NEPHROPLUS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Nephrocare Health Services (NEPHROPLUS) is ₹443.20 (median value). With the current market price of ₹699.10, this represents a -36.6% variance from our estimated fair value.
The valuation range spans from ₹209.73 to ₹1582.46, indicating ₹209.73 - ₹1582.46.
Is NEPHROPLUS undervalued or overvalued?
Based on our multi-method analysis, Nephrocare Health Services (NEPHROPLUS) appears to be trading above calculated value by approximately 36.6%.
NEPHROPLUS Financial Health — Key Ratios vs Industry Benchmarks
Nephrocare Health Services financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 15.25 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 10.7% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.75x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
NEPHROPLUS Cash Flow Quality — Operating & Free Cash Flow
Nephrocare Health Services operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹233 Cr | ₹37 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹135 Cr | ₹73 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹72 Cr | ₹46 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹11 Cr | ₹-27 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹14 Cr | ₹-51 Cr | Positive Operating Cash Flow | 6/10 |